Search results for "Drugs"

showing 10 items of 747 documents

Phencyclidine-induced disruption of oscillatory activity in prefrontal cortex: Effects of antipsychotic drugs and receptor ligands

2016

The non-competitive NMDA receptor (NMDA-R) antagonist phencyclidine (PCP) markedly disrupts thalamocortical activity, increasing excitatory neuron discharge and reducing low frequency oscillations (LFO, <4Hz) that temporarily group neuronal discharge. These actions are mainly driven by PCP interaction with NMDA-R in GABAergic neurons of the thalamic reticular nucleus and likely underlie PCP psychotomimetic activity. Here we report that classical (haloperidol, chlorpromazine, perphenazine) and atypical (clozapine, olanzapine, quetiapine, risperidone, ziprasidone, aripripazole) antipsychotic drugs - but not the antidepressant citalopram - countered PCP-evoked fall of LFO in the medial prefron…

Male0301 basic medicineOscillationsmedicine.drug_classDopamine AgentsAtypical antipsychoticPhencyclidineKainate receptorPharmacologyNeurotransmissionPrefrontal cortex03 medical and health scienceschemistry.chemical_compoundSerotonin Agents0302 clinical medicineHistamine AgentsmedicineAnimalsPharmacology (medical)NMDA receptor antagonistsAntipsychotic drugsRats WistarChlorpromazineEvoked PotentialsPhencyclidineBiological PsychiatryPharmacologyRacloprideAnalysis of VarianceDose-Response Relationship DrugFourier AnalysisChemistryElectroencephalographyPsychotomimeticRatsPsychiatry and Mental health030104 developmental biologyNeurologynervous systemSchizophreniaNBQXNeurology (clinical)Excitatory Amino Acid AntagonistsNeuroscience030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drug
researchProduct

Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients

2016

Adult-onset Still’s disease (AOSD) is a systemic inflammatory condition of unknown aetiology characterized by typical episodes of spiking fever, evanescent rash, arthralgia, leukocytosis and hyperferritinemia. Given the lack of data in Italian series, we promote a multicentric data collection to characterize the clinical phenotype of Italian patients with AOSD. Data from 245 subjects diagnosed with AOSD were collected by 15 centres between March and May 2013. The diagnosis was made following Yamaguchi’s criteria. Data regarding clinical manifestations, laboratory features, disease course and treatments were reported and compared with those presented in other published series of different et…

Male0301 basic medicinePediatricsAdult-onset Still's diseaseSettore MED/16 - REUMATOLOGIALeukocytosisClinical presentationArthritisComorbidityDiseaseLaboratory finding0302 clinical medicineAdrenal Cortex HormonesLeukocytosisAdult-onset Still’s diseaseBiologic drugsMedicine (all)General MedicineMiddle AgedRashRetrospective studyTreatment OutcomeItalyAdult-onset Still’s disease; Biologic drugs; Clinical presentation; Laboratory findings; Retrospective study; Rheumatology; Medicine (all)Antirheumatic AgentsFemalemedicine.symptomStill's Disease Adult-OnsetAdultLaboratory findingsmedicine.medical_specialtyAdolescentFeverNOYoung Adult03 medical and health sciencesRheumatologyInternal medicinemedicineHumansAgedRetrospective Studies030203 arthritis & rheumatologybusiness.industryAdult-onset Still’s disease; Biologic drugs; Clinical presentation; Laboratory findings; Retrospective study; RheumatologyRetrospective cohort studymedicine.diseaseNeutrophiliaRheumatologySurgery030104 developmental biologybusinessBiologic drug
researchProduct

Involvement of Bax and Bcl-2 in induction of apoptosis by essential oils of three Lebanese Salvia species in human prostate cancer cells

2018

Prostate cancer is one of the most common forms of cancer in men, and research to find more effective and less toxic drugs has become necessary. In the frame of our ongoing program on traditionally used Salvia species from the Mediterranean Area, here we report the biological activities of Salvia aurea, S. judaica and S. viscosa essential oils against human prostate cancer cells (DU-145). The cell viability was measured by 3(4,5-dimethyl-thiazol-2-yl)2,5-diphenyl-tetrazolium bromide (MTT) test and lactate dehydrogenase (LDH) release was used to quantify necrosis cell death. Genomic DNA, caspase-3 activity, expression of cleaved caspase-9, B-cell lymphoma 2 (Bcl-2) and Bcl-2 associated X (Ba…

Male0301 basic medicineSalvia miltiorrhiza<i>Salvia</i>; essential oil; prostate cancer; apoptosis; reactive oxygen specieslcsh:ChemistryProstate cancer0302 clinical medicineSalvialcsh:QH301-705.5Spectroscopybcl-2-Associated X Proteinreactive oxygen speciesCamphanesapoptosisGeneral Medicineprostate cancerComputer Science ApplicationsGene Expression Regulation NeoplasticProto-Oncogene Proteins c-bcl-2030220 oncology & carcinogenesisApoptosis Essential oil Prostate cancer Reactive oxygen species SalviaProgrammed cell deathSalvia; apoptosis; essential oil; prostate cancer; reactive oxygen speciesPanax notoginsengDNA FragmentationBiologyArticleCatalysisessential oilInorganic Chemistry03 medical and health sciencesBcl-2-associated X proteinCell Line TumorOils VolatilemedicineHumansViability assayPhysical and Theoretical ChemistryMolecular BiologyCell ProliferationCell growthOrganic ChemistryProstatic NeoplasmsCancerSettore CHIM/06 - Chimica Organicamedicine.diseaseapoptosi030104 developmental biologylcsh:Biology (General)lcsh:QD1-999ApoptosisCancer cellCancer researchbiology.proteinDrugs Chinese Herbal
researchProduct

Anti-tumour necrosis factor-α antibodies and B cell homeostasis in human inflammatory bowel diseases

2017

Background The expression of CD70 on T cells is greatly enhanced by antigen-presenting cell (APC)-associated signals, such as tumour necrosis factor(TNF)-α, which is constitutionally high in patients with inflammatory bowel disease (IBD). Experimentally, the chronic activation of CD27 as a result of the constitutive expression of CD70 leads to the demise of B cells in bone marrow (BM) and the secondary lymphoid organs. The aim of this study was to assess the number and phenotype of circulating B cell in untreated IBD patients and their counterparts treated with biological anti-TNF drugs. Methods The study involved 13 untreated IBD patients, 36 IBD patients treated with biological drugs, and…

Male0301 basic medicineT-LymphocytesImmunophenotypingB cell homeostasisBiological drugs; Inflammatory bowel diseases; Plasmablasts; TNF-αHomeostasisImmunology and AllergyCD20B-LymphocytesbiologyB-LymphocyteAntibodies MonoclonalMiddle AgedFlow Cytometrymedicine.anatomical_structureFemaleTumor necrosis factor alphaImmunotherapyAntibodyPlasmablastsHumanAdultAdolescentBiological drugImmunologyB-Lymphocyte SubsetsPlasmablastCD19ImmunophenotypingYoung Adult03 medical and health sciencesHomeostasimedicineHumansBiological drugsB cellB-Lymphocyte SubsetPharmacologyTumor Necrosis Factor-alphabusiness.industryInflammatory Bowel DiseaseInflammatory Bowel Diseases030104 developmental biologyT-LymphocyteTNF-αImmunologybiology.proteinBone marrowbusinessCD27 LigandInternational Immunopharmacology
researchProduct

Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge

2017

Statins, the 3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase inhibitors, are widely prescribed for treatment of hypercholesterolemia. Although statins are generally well tolerated, up to ten percent of statin-treated patients experience myalgia symptoms, defined as muscle pain without elevated creatinine phosphokinase (CPK) levels. Myalgia is the most frequent reason for discontinuation of statin therapy. The mechanisms underlying statin myalgia are not clearly understood. To elucidate changes in gene expression associated with statin myalgia, we compared profiles of gene expression in skeletal muscle biopsies from patients with statin myalgia who were undergoing statin re-challenge (cases)…

Male0301 basic medicinemyalgiaGene Expressionlcsh:MedicineApoptosis030204 cardiovascular system & hematologyPathology and Laboratory MedicineBioinformaticsBiochemistry0302 clinical medicineMedicine and Health SciencesGene Regulatory Networkslcsh:ScienceMusculoskeletal SystemEnergy-Producing OrganellesMyositisRegulation of gene expressionMultidisciplinaryCell DeathbiologyMusclesDrugsMiddle AgedMitochondriaCell ProcessesHMG-CoA reductaseFemalelipids (amino acids peptides and proteins)AnatomyCellular Structures and Organellesmedicine.symptomResearch ArticleSenescencemedicine.medical_specialtyStatinmedicine.drug_classPainBioenergeticsPolymorphism Single Nucleotide03 medical and health sciencesSigns and SymptomsDiagnostic MedicineInternal medicineGeneticsmedicineHumansGene Regulationcardiovascular diseasesMuscle SkeletalAgedPharmacologybusiness.industrylcsh:RStatinsBiology and Life SciencesComputational Biologynutritional and metabolic diseasesMyalgiaCell Biologymedicine.disease030104 developmental biologyEndocrinologyGene Expression RegulationSkeletal MusclesLeukocytes Mononuclearbiology.proteinProtein prenylationlcsh:QHydroxymethylglutaryl-CoA Reductase InhibitorsSLCO1B1businessPLOS ONE
researchProduct

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.

2016

Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; BACKGROUND Chronic graft-versus-host disease (GVHD) is the leading cause of later illness and death after allogeneic hematopoietic stem-cell transplantation. We hypothesized that the inclusion of antihuman T-lymphocyte immune globulin (ATG) in a myeloablative conditioning regimen for patients with acute leukemia would result in a significant reduction in chronic GVHD 2 years after allogeneic peripheral-blood stem-cell transplantation from an HLA-identical sibling. METHODS We conducted a prospective, multicenter, open-label, randomized phase 3 study of ATG as part of …

Male:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Models Statistical::Proportional Hazards Models [Medical Subject Headings]T-LymphocytesPhases of clinical researchGraft vs Host Disease:Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]Linfocitos t:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Immunosuppressive Agent0302 clinical medicineTrasplante homólogoEstudios prospectivosMedicineCumulative incidenceProspective StudiesProspective cohort studyChildTransplantation Homologou:Chemicals and Drugs::Amino Acids Peptides and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Immune Sera::Antilymphocyte Serum [Medical Subject Headings]Acute leukemia:Anatomy::Cells::Blood Cells::Leukocytes::Leukocytes Mononuclear::Lymphocytes::T-Lymphocytes [Medical Subject Headings]:Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Chronic Disease [Medical Subject Headings]:Named Groups::Persons::Age Groups::Child::Child Preschool [Medical Subject Headings]Medicine (all)IncidenceSuero antilinfocíticoGeneral MedicineMiddle AgedModelos de riesgos proporcionales3. Good healthHumanosSurvival Rate030220 oncology & carcinogenesis:Named Groups::Persons::Age Groups::Adolescent [Medical Subject Headings]Child PreschoolFemale:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Immunologic Factors::Immunosuppressive Agents [Medical Subject Headings]Immunosuppressive AgentsHumanHomologousAdultmedicine.medical_specialty:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings]:Named Groups::Persons::Age Groups::Adult::Young Adult [Medical Subject Headings]AdolescentEnfermedad injerto contra huéspedDisease-Free Survival03 medical and health sciencesYoung AdultInternal medicine:Named Groups::Persons::Age Groups::Adult [Medical Subject Headings]HumansTransplantation HomologousSupervivencia sin enfermedadPreschoolSurvival rate:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Disease-Free Survival [Medical Subject Headings]:Named Groups::Persons::Age Groups::Child [Medical Subject Headings]Antilymphocyte SerumProportional Hazards ModelsTransplantationbusiness.industryEnfermedad crónicamedicine.diseaseInmunosupresoresAnti-thymocyte globulinSurgeryTransplantation:Diseases::Immune System Diseases::Graft vs Host Disease [Medical Subject Headings]Prospective Studie:Analytical Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures Operative::Transplantation::Transplantation Homologous [Medical Subject Headings]Graft-versus-host diseaseT-Lymphocyte:Check Tags::Female [Medical Subject Headings]Chronic DiseaseProportional Hazards ModelAdolescent; Adult; Antilymphocyte Serum; Child; Child Preschool; Chronic Disease; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Survival Rate; T-Lymphocytes; Transplantation Homologous; Young Adult; Medicine (all)business030215 immunology
researchProduct

Gut microbiota steroid sexual dimorphism and its impact on gonadal steroids: influences of obesity and menopausal status

2020

[Background]: Gonadal steroid hormones have been suggested as the underlying mechanism responsible for the sexual dimorphism observed in metabolic diseases. Animal studies have also evidenced a causal role of the gut microbiome and metabolic health. However, the role of sexual dimorphism in the gut microbiota and the potential role of the microbiome in influencing sex steroid hormones and shaping sexually dimorphic susceptibility to disease have been largely overlooked. Although there is some evidence of sex-specific differences in the gut microbiota diversity, composition, and functionality, the results are inconsistent. Importantly, most of these studies have not taken into account the go…

Male:Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cross-Sectional Studies [Medical Subject Headings]PhysiologyGut flora:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Mice:Chemicals and Drugs::Hormones Hormone Substitutes and Hormone Antagonists::Hormones::Gonadal Hormones [Medical Subject Headings]0302 clinical medicineOverweight persons:Organisms::Eukaryota::Animals [Medical Subject Headings]TestosteroneProgesteronaGonadal Steroid HormonesTestosteronaTestosteroneProgesterone:Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings]Sex Characteristics0303 health sciencesMicrobiotaIntestins -- MalaltiesMiddle AgedSex ; Gender ; Gonadal steroids ; Testosterone ; Progesterone ; Microbiome ; Sexual dimorphism.Persones obeses3. Good healthMenopause:Phenomena and Processes::Microbiological Phenomena::Microbiota [Medical Subject Headings]Intestins -- MicrobiologiaCaracteres sexualeslcsh:QR100-130Female:Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Climacteric::Menopause [Medical Subject Headings]SexAnimal studiesIntestines -- DiseasesMenopauseMenopausaAdultMicrobiology (medical):Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Sex Characteristics [Medical Subject Headings]:Check Tags::Male [Medical Subject Headings]SexoSteroid biosynthesisBiologyIntestines -- Microbiologydigestive systemMicrobiologylcsh:Microbial ecology:Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies [Medical Subject Headings]03 medical and health sciencesSexual dimorphismmedicineAnimalsHumansObesityMicrobiome:Persons::Persons::Age Groups::Adult [Medical Subject Headings]Aged030304 developmental biology:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Mice [Medical Subject Headings]ResearchGender:Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]medicine.diseasebiology.organism_classificationObesityGastrointestinal Microbiome:Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity [Medical Subject Headings]Gonadal steroidsSexual dimorphismCross-Sectional Studies:Check Tags::Female [Medical Subject Headings]Case-Control StudiesIdentidad de géneroMicrobiome030217 neurology & neurosurgeryMicrobiome
researchProduct

Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

2017

Prevenció; Atac d'angioedema; Inhibidor C1 Prevención; Ataque de angioedema; Inhibidor C1 Prevention; Angioedema attack; C1 inhibitor BACKGROUND: Hereditary angioedema is a disabling, potentially fatal condition caused by deficiency (type I) or dysfunction (type II) of the C1 inhibitor protein. In a phase 2 trial, the use of CSL830, a nanofiltered C1 inhibitor preparation that is suitable for subcutaneous injection, resulted in functional levels of C1 inhibitor activity that would be expected to provide effective prophylaxis of attacks. METHODS: We conducted an international, prospective, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase 3 trial to evaluate the …

Male:aminoácidos péptidos y proteínas::péptidos::serpinas::proteínas inactivadoras del complemento C1::proteína inhibidora del complemento C1 [COMPUESTOS QUÍMICOS Y DROGAS]0301 basic medicine:Otros calificadores::Otros calificadores::/prevención & control [Otros calificadores]Enzims proteolítics - InhibidorsSelf AdministrationSeverity of Illness Indexlaw.inventionC1-inhibitorSubcutaneous injection0302 clinical medicineRandomized controlled triallawCross-Over StudiesHereditary Angioedema Types I and IIbiologyEdema - PrevencióGeneral Medicine:Cardiovascular Diseases::Vascular Diseases::Angioedema::Angioedemas Hereditary [DISEASES]AnesthesiaHereditary angioedema:Other subheadings::Other subheadings::/administration & dosage [Other subheadings]Female:Amino Acids Peptides and Proteins::Peptides::Serpins::Complement C1 Inactivator Proteins::Complement C1 Inhibitor Protein [CHEMICALS AND DRUGS]medicine.symptomComplement C1 Inhibitor Protein:enfermedades cardiovasculares::enfermedades vasculares::angioedema::angioedemas hereditarios [ENFERMEDADES]AdultRiskmedicine.medical_specialtyInjections Subcutaneous:Aminoácidos Péptidos y Proteínas::Péptidos::Serpinas::Proteínas Inactivadoras del Complemento 1::Proteína Inhibidora del Complemento C1 [COMPUESTOS QUÍMICOS Y DROGAS]Placebo:Other subheadings::Other subheadings::/prevention & control [Other subheadings]03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumans:Therapeutics::Drug Therapy::Drug Administration Routes::Injections::Injections Subcutaneous [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]:Otros calificadores::Otros calificadores::/administración & dosificación [Otros calificadores]Dose-Response Relationship DrugAngioedemabusiness.industry:Terapéutica::Tratamiento Farmacológico::Vías de Administración de Medicamentos::Inyecciones::Inyecciones Subcutáneas [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Injeccions hipodèrmiquesmedicine.diseaseCrossover studyClinical trial:terapéutica::farmacoterapia::vías de administración de medicamentos::inyecciones::inyecciones subcutáneas [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]030104 developmental biology030228 respiratory systembiology.proteinbusinessNew England Journal of Medicine
researchProduct

Phencyclidine inhibits the activity of thalamic reticular gamma-aminobutyric acidergic neurons in rat brain.

2014

Póster presentado en el IX Simposi de Neurobiologia Experimental, celebrado los días 22 y 23 de octubre de 2014 en Barcelona y organizado por la Societat Catalana de Biologia del Institut d'Estudis Catalans

MaleAction PotentialsPhencyclidinePrefrontal CortexLocal field potentialGABA AntagonistsThalamusthalamocortical networksNeural PathwaysmedicinePremovement neuronal activityAnimalsNMDA receptor antagonistsAntipsychotic drugsGABAergic NeuronsRats WistarPrefrontal cortexReceptorPhencyclidineClozapineBiological PsychiatryClozapineAnalysis of VarianceChemistryRatsschizophreniaElectrophysiologyParvalbuminspsychotic symptomsExcitatory postsynaptic potentialHallucinogensNeurosciencemedicine.drugBiological psychiatry
researchProduct

Gender differences in the effects of haloperidol on avoidance conditioning in mice

1995

Abstract Gender differences in the effects of haloperidol (0.07S mg/kg per day for 5 days) on avoidance conditioning were evaluated. We also studied performance of the subjects free of the drug and the acute effects of haloperidol in animals trained without drug 48 h after the last haloperidol administration. Latencies of escape and avoidance responses, number of nonresponses, escapes, avoidances, crossings during the adaptation period, crossings during intertrial intervals, and total crossings per minute were analyzed. This dosage impaired conditioning of the male animals but did not attain the same effects on females. Haloperidol did not deteriorate performance of the task when it had bee…

MaleAcute effectsNeuroleptic DrugsClinical BiochemistryPhysiologyMice Inbred StrainsMotor behaviorMotor ActivityToxicologyBiochemistryDevelopmental psychologyMiceBehavioral NeuroscienceAvoidance LearningHaloperidolmedicineAnimalsBiological PsychiatryPharmacologySex CharacteristicsDose-Response Relationship DrugAvoidance ConditioningDopamine antagonistToxicityHaloperidolConditioningFemalePsychologyPsychomotor Performancemedicine.drugPharmacology Biochemistry and Behavior
researchProduct